Published in Drug Alcohol Depend on September 15, 2010
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect (2013) 2.09
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis (2011) 0.95
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS (2015) 0.90
A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis (2014) 0.84
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis (2011) 0.82
A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One (2014) 0.81
Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis (2015) 0.77
Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev (2017) 0.75
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Global overview of injecting drug use and HIV infection among injecting drug users. AIDS (2004) 5.45
How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (2010) 5.08
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (2010) 3.59
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction (2011) 2.95
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.56
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction (2006) 2.46
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol (2013) 2.08
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health (2005) 2.01
Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction (2007) 1.95
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction (2006) 1.87
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol (2003) 1.84
Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction (2007) 1.81
Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol (2006) 1.78
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Adolescent alcohol and tobacco use and early socioeconomic position: the ALSPAC birth cohort. Pediatrics (2011) 1.60
Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol (2004) 1.57
Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction (2013) 1.56
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Stat Q (2006) 1.43
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Intrauterine exposure to alcohol and tobacco use and childhood IQ: findings from a parental-offspring comparison within the Avon Longitudinal Study of Parents and Children. Pediatr Res (2008) 1.38
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust (2012) 1.33
Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol (2011) 1.32
Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health (2014) 1.30
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction (2009) 1.30
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis (2008) 1.23
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.23
Socio-economic status in childhood and later alcohol use: a systematic review. Addiction (2007) 1.21
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health (2011) 1.20
Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS (2005) 1.18
Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev (2009) 1.16
Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr (2006) 1.15
Parental drug use, early adversities, later childhood problems and children's use of tobacco and alcohol at age 10: birth cohort study. Addiction (2008) 1.14
Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. J Public Health (Oxf) (2013) 1.13
Low incidence of hepatitis C virus among prisoners in Scotland. Addiction (2013) 1.11
Characterizing patterns of smoking initiation in adolescence: comparison of methods for dealing with missing data. Nicotine Tob Res (2011) 1.06
The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction (2004) 1.05
Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend (2013) 1.03
Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduct J (2013) 1.02
Patterns of alcohol use in early adolescence predict problem use at age 16. Alcohol Alcohol (2012) 1.02
Policy resistance to harm reduction for drug users and potential effect of change. BMJ (2010) 0.98
Over a decade of syringe exchange: results from 1997 UK survey. Addiction (2002) 0.98
Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact. Drug Alcohol Depend (2011) 0.96
Outcomes of childhood conduct problem trajectories in early adulthood: findings from the ALSPAC study. Eur Child Adolesc Psychiatry (2013) 0.96
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol (2009) 0.95
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open (2013) 0.95
Testing a level of response to alcohol-based model of heavy drinking and alcohol problems in 1,905 17-year-olds. Alcohol Clin Exp Res (2011) 0.95
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis (2012) 0.95
Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. Addiction (2005) 0.95
HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS (2005) 0.94
Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources. Am J Epidemiol (2014) 0.94
Maternal smoking during pregnancy and offspring smoking initiation: assessing the role of intrauterine exposure. Addiction (2014) 0.94
Reporting bias and self-reported drug use. Addiction (2005) 0.94
Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction (2015) 0.93
Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ (2013) 0.91
Comparison of ethyl glucuronide in hair with self-reported alcohol consumption. Alcohol Alcohol (2012) 0.91
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS (2015) 0.90
Early life socio-economic position and later alcohol use: birth cohort study. Addiction (2012) 0.90
Trends in overdose deaths from drug misuse in Europe: what do the data tell us? Addiction (2008) 0.90
Multiple parameter evidence synthesis--a potential solution for when information on drug use and harm is in conflict. Addiction (2013) 0.90
Changes in HIV prevalence and risk among new injecting drug users in a Russian city of high HIV prevalence. J Acquir Immune Defic Syndr (2008) 0.88
Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep (2013) 0.88
Using Mendelian randomisation to infer causality in depression and anxiety research. Depress Anxiety (2013) 0.88
Directional relationships between alcohol use and antisocial behavior across adolescence. Alcohol Clin Exp Res (2014) 0.87
The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls. BMC Public Health (2010) 0.87
Conduct problem trajectories and alcohol use and misuse in mid to late adolescence. Drug Alcohol Depend (2013) 0.86
Latent trajectory classes for alcohol-related blackouts from age 15 to 19 in ALSPAC. Alcohol Clin Exp Res (2014) 0.85
Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. Addiction (2008) 0.85
The relationship between alcohol use and injecting drug use: impacts on health, crime and wellbeing. Drug Alcohol Depend (2012) 0.85
Transmission of hepatitis C--are noninjecting cocaine users at risk? Subst Use Misuse (2002) 0.84
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
A systematic review of interventions to increase the uptake of opiate substitution therapy in injecting drug users. J Public Health (Oxf) (2010) 0.83
Childhood behaviour problems predict crime and violence in late adolescence: Brazilian and British birth cohort studies. Soc Psychiatry Psychiatr Epidemiol (2014) 0.83
Cannabis and psychosis. Lancet (2007) 0.83
Association of maternal smoking with child cotinine levels. Nicotine Tob Res (2013) 0.82
The association between depressive symptoms from early to late adolescence and later use and harmful use of alcohol. Eur Child Adolesc Psychiatry (2014) 0.82
Risk adjustment of heroin treatment outcomes for comparative performance assessment in England. Addiction (2012) 0.81
Could a peer-led intervention increase uptake of chlamydia screening? A proof of principle pilot study. J Fam Plann Reprod Health Care (2012) 0.80
HCV treatment as prevention in prison: key issues. Hepatology (2014) 0.80
Early life influences on the risk of injecting drug use: case control study based on the Edinburgh Addiction Cohort. Addiction (2012) 0.80
Genomic influences on alcohol problems in a population-based sample of young adults. Addiction (2015) 0.79
Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base? Addiction (2014) 0.78
Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. Int J Drug Policy (2012) 0.78
The health, social and educational needs of children who have survived meningitis and septicaemia: the parents' perspective. BMC Public Health (2013) 0.78